Vistagen Therapeutics Faces Class Action for Securities Fraud, Investors Can Claim Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Businesswire
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Vistagen Therapeutics for violating §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statements: The complaint alleges that Vistagen misled the market by falsely suggesting that its fasedienol drug candidate was likely to succeed in Phase 3 trials, downplaying the risks of failure in clinical studies, which misled investors about the company's prospects.
- Loss Risks: Following the revelation of the truth about Vistagen, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, potentially leading to a significant loss of investor trust.
- Legal Consultation: The Schall Law Firm offers free consultations and encourages affected investors to seek legal support in the class action to recover losses due to the company's failure to meet its legal obligations.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VTGN is 15.50 USD with a low forecast of 12.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.671
Low
12.00
Averages
15.50
High
19.00
Current: 0.671
Low
12.00
Averages
15.50
High
19.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
